Spleen-targeting mRNA vaccine: a “precision bombardment” toward curative treatment of liver cancer
1. The high barrier in liver cancer therapy, unresponsive immune cells
Liver cancer is one of the cancers worldwide with very low survival rates. In particular, patients with advanced hepatocellular carcinoma (HCC) have found it difficult to achieve therapeutic benefit even after receiving conventional neoantigen vaccines because the body's defensive T cells are not sufficiently activated. This is because cancer cells cleverly evade immune surveillance.
2. Birth of the spleen‑targeted vaccine (STNvac): triumph of precise delivery
The research team developed a novel mRNA vaccine, STNvac, that directly attacks the spleen, the central hub of immune responses. It was engineered so that the vaccine’s genetic information is delivered to the spleen with very high efficiency after only three administrations. In experimental liver cancer models, the results confirmed the possibility of complete tumor regression, and survival was statistically highly significant (p < 0.0001) improvement.
3. ISG15 signaling: a powerful trumpet that awakens immune troops
One of the key findings of this study is the role of ISG15 (interferon‑stimulated gene 15) induced after vaccination. When STNvac is administered, the ISG15 signal is distinctly activated in the body; this molecule acts as a natural catalyst that further motivates immune cells and enhances antitumor activity, thereby solidifying the therapeutic effect of the vaccine.
4. Future significance and outlook
This robust mRNA delivery platform that exploits the spleen is expected to become a hopeful personalized therapeutic option for patients with advanced liver cancer. The investigators anticipate that the technology can be broadly extended to the treatment of other solid tumors and that it will achieve remarkable results in forthcoming human clinical trials.
The efficacy of neoantigen vaccine for advanced hepatocellular carcinoma (HCC) is limited largely due to insufficient T cell mobilization and activation. Herein, we develop a spleen-targeted neoantigen mRNA vaccine (STNvac) with highly efficient spleen-selective mRNA transfection. Using a three-dose vaccination regimen, STNvac demonstrates remarkable therapeutic efficacy in orthotopic HCC model with a high likelihood of complete tumor regression and significantly improved survival rates (p < 0.0001). Notably, we identify a distinct ISG15
Existing vaccines struggled to awaken the immune system of liver‑cancer patients; the spleen‑targeting approach fully activates it. This is highly significant because even patients with advanced, hard‑to‑treat HCC can now maximize their own immunity to overcome the cancer and return to a healthy daily life.